检验医学与临床
檢驗醫學與臨床
검험의학여림상
JOURNAL OF LABORATORY MEDICINE AND CLINICAL SCIENCES
2014年
1期
54-56
,共3页
血液透析%血管紧张素Ⅱ受体拮抗药%血管紧张素转换酶抑制剂%贫血
血液透析%血管緊張素Ⅱ受體拮抗藥%血管緊張素轉換酶抑製劑%貧血
혈액투석%혈관긴장소Ⅱ수체길항약%혈관긴장소전환매억제제%빈혈
hemodialysis%angiotensin Ⅱ receptor antagonist drug%angiotensin-converting enzyme I inhib-itor%anemia
目的:观察血管紧张素Ⅱ受体拮抗药(ARB)和血管紧张素转换酶抑制剂(ACEI)对维持性血液透析(MHD)的终末期肾衰竭(ESRF)患者应用重组人红细胞生成素(r-HuEPO)对贫血疗效的影响。方法根据行M HD的ESRF患者所用降压药的不同将其分为以下三组:r-HuEPO+ACEI组15例,r-HuEPO+ARB组15例,对照组15例(r-HuEPO+钙离子拮抗药);检测用药第0、4、8、16周时的红细胞(RBC)计数及血红蛋白(Hb)。结果r-HuEPO+ACEI组与r-HuEPO+ ARB组在治疗0、4、8、16周时的RBC、Hb值组内比较,差异无统计学意义(P>0.05),组间比较差异无统计学意义( P>0.05);而对照组治疗16周后的RBC、H b均明显较治疗前增高( P<0.05),与r-HuEPO+ACEI组、r-HuEPO+ ARB组治疗16周比较,差异均具有统计学意义(P<0.05)。结论 ARB及ACEI均可影响r-HuEPO治疗贫血的疗效。
目的:觀察血管緊張素Ⅱ受體拮抗藥(ARB)和血管緊張素轉換酶抑製劑(ACEI)對維持性血液透析(MHD)的終末期腎衰竭(ESRF)患者應用重組人紅細胞生成素(r-HuEPO)對貧血療效的影響。方法根據行M HD的ESRF患者所用降壓藥的不同將其分為以下三組:r-HuEPO+ACEI組15例,r-HuEPO+ARB組15例,對照組15例(r-HuEPO+鈣離子拮抗藥);檢測用藥第0、4、8、16週時的紅細胞(RBC)計數及血紅蛋白(Hb)。結果r-HuEPO+ACEI組與r-HuEPO+ ARB組在治療0、4、8、16週時的RBC、Hb值組內比較,差異無統計學意義(P>0.05),組間比較差異無統計學意義( P>0.05);而對照組治療16週後的RBC、H b均明顯較治療前增高( P<0.05),與r-HuEPO+ACEI組、r-HuEPO+ ARB組治療16週比較,差異均具有統計學意義(P<0.05)。結論 ARB及ACEI均可影響r-HuEPO治療貧血的療效。
목적:관찰혈관긴장소Ⅱ수체길항약(ARB)화혈관긴장소전환매억제제(ACEI)대유지성혈액투석(MHD)적종말기신쇠갈(ESRF)환자응용중조인홍세포생성소(r-HuEPO)대빈혈료효적영향。방법근거행M HD적ESRF환자소용강압약적불동장기분위이하삼조:r-HuEPO+ACEI조15례,r-HuEPO+ARB조15례,대조조15례(r-HuEPO+개리자길항약);검측용약제0、4、8、16주시적홍세포(RBC)계수급혈홍단백(Hb)。결과r-HuEPO+ACEI조여r-HuEPO+ ARB조재치료0、4、8、16주시적RBC、Hb치조내비교,차이무통계학의의(P>0.05),조간비교차이무통계학의의( P>0.05);이대조조치료16주후적RBC、H b균명현교치료전증고( P<0.05),여r-HuEPO+ACEI조、r-HuEPO+ ARB조치료16주비교,차이균구유통계학의의(P<0.05)。결론 ARB급ACEI균가영향r-HuEPO치료빈혈적료효。
Objective To observe the influence of angiotensin Ⅱ receptor antagonist(ARB) I and angiotensin-converting enzyme inhibitors (ACEI) on the efficacy of recombinant human erythropoietin (r-HuEPO ) for improving anemia in the maintenance hemodialysis(MHD) patients with end-stage renal failure(ESRF) .Methods MHD pa-tients with ESRF were divided into 3 groups according to using the different antihypertensive drugs :r-HuEPO +ACEI group(15 cases) ,r-HuEPO + ARB group(15 cases) and the control group(r-HuEPO + calcium antagonists , 15 cases) .The RBC counting and hemoglobin (Hb) were detected before treatment and in 0 ,4 ,8 ,16 weeks after treatment .Results The values of RBC counting and Hb in 0 ,4 ,8 ,16 weeks after treatment had no statistically sig-nificant differences in the intra-group comparison and the inter-group comparison of the r-HuEPO+ACEI group and the r-HuEPO+ARB group(P>0 .05) .RBC counting and Hb after 16-week treatment in the control group were sig-nificantly higher than that before treatment(P<0 .05) ,compared with the r-HuEPO+ACEI group and the r-HuEPO+ARB group ,the differences were statistically significant (P <0 .05) .Conclusion ARB and ACEI may affect the ef-ficacy of r-HuEPO for treating anemia .